INBX · Inhibrx Biosciences, Inc. · Executive Compensation

$112.04 +2.69 (+2.46%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.54B

14.72M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark P. Lappe	Chief Executive Officer and Chairman of the Board of Directors	$695,250	$1,700,000	—	—	$479,723	$17,500	$2,892,473
David J. Matly	M.B.A. President	$589,170	—	—	$524,285	$304,985	$17,500	$1,435,940
Kelly D. Deck	C.P.A. Chief Financial Officer	$493,485	—	—	$157,286	$255,425	$17,500	$923,696

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark P. Lappe	Chief Executive Officer and Chairman of the Board of Directors	$695,250	—	—	$3,573,408	$417,150	$5,975	$4,691,783
Kelly D. Deck	C.P.A. Chief Financial Officer	$460,100	$1,500,000	—	$2,084,488	$207,045	$15,621	$4,267,254
Brendan P. Eckelman	Former Chief Scientific Officer	$535,600	—	—	$2,084,488	—	$7,504	$2,627,592

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark P. Lappe	Chief Executive Officer and Chairman of the Board of Directors	$675,000	—	—	$1,706,771	$405,000	$15,250	$2,802,021
Brendan P. Eckelman	Former Chief Scientific Officer	$520,000	—	—	$682,708	$234,000	$15,250	$1,451,958
Kelly D. Deck	C.P.A. Chief Financial Officer	$430,000	—	—	$512,031	$193,500	$13,368	$1,148,899

Executive changes

Person	Role	Change	Effective	Filed
Brendan P. Eckelman, Ph.D.	EVP, Chief Scientific Officer	Resigned	2025-03-31	2025-04-01
David J. Matly, M.B.A.	President	Appointed	2025-04-01	2025-04-01

Key facts CIK 2007919 CUSIP 45720N103 13F (30d) 4 filings 4 filers Visit website Investor relations